Mean oral bioavailability in Swiss albino male mice at 2.5 mg/kg per compound (administered in a mixture of 5 compounds to 3 mice) assessed by LCMS/MS.
Mean volume of distribution at steady state in Swiss albino male mice at 1 mg/kg per compound (administered iv in a mixture of 5 compounds to 3 mice) assessed by LCMS/MS.
Mean plasma concentration at 24h in Swiss albino male mice at 2.5 mg/kg per compound (administered orally in a mixture of 5 compounds to 3 mice) assessed by LCMS/MS.
Mean plasma concentration at 4h in Swiss albino male mice at 2.5 mg/kg per compound (administered orally in a mixture of 5 compounds to 3 mice) assessed by LCMS/MS.
Mean time to peak plasma concentration in Swiss albino male mice at 2.5 mg/kg per compound (administered orally in a mixture of 5 compounds to 3 mice) assessed by LCMS/MS.
Percentage of parent compound remaining after incubation for 30 minutes with cyropreserved human hepatocytes at a concentration of 1uM compound and 1 million cells/uL, determined by LCMS/MS
Percentage of parent compound remaining after incubation for 30 minutes with cyropreserved mouse hepatocytes at a concentration of 1uM compound and 0.5 million cells/uL, determined by LCMS
Percentage of parent compound remaining after incubation for 90 minutes with cyropreserved mouse hepatocytes at a concentration of 1uM compound and 0.5 million cells/uL, determined by LCMS